Klaria and Purdue Pharma have announced they have entered into an exclusive development agreement for KL-01401 (Epinephrine Oromucosal Film).

KL-01401 is a developmental stage formulation of epinephrine for emergency treatment of severe anaphylactic reactions in patients who are at increased risk for anaphylaxis.  KL-01401 will be co-developed by Klaria and Purdue Pharma (Canada). The development agreement includes exclusive global license and supply options for the independently associated Purdue/Napp/Mundipharma network of companies upon achievement of defined milestones.

Under the terms of the agreement, the total value of all milestones achievable is 55.2 million US Dollars.  In addition, Klaria will receive mid-to-upper single digit royalties on net sales. Further terms of the agreements give Klaria exclusive manufacturing rights to supply the global market with KL-01401.

In order to complete the agreement with Purdue, Klaria AB has also added epinephrine to its license agreement with Uppsalagruppen Medical AB.  In the agreement between Klaria and Uppsalagruppen, Uppsalagruppen will receive a four precent royalty on Klaria’s net income from sales of KL-01401.

“We are extremely pleased and encouraged to enter into this agreement with Purdue – our second collaboration to date. This agreement combines the strengths of our patented drug delivery platform with a partner who is a leader in development and commercialization of innovative treatments. We are confident that the result of our partnership will meet an unmet medical need for patients relying on epinephrine in the event of a severe allergic reaction,” said Scott Boyer, CEO, Klaria.